第14届帕金森氏病和运动障碍国际大会。

Idrugs Pub Date : 2010-08-01

Donald Grosset, Andrew Grosset

{"title":"第14届帕金森氏病和运动障碍国际大会。","authors":"Donald Grosset, Andrew Grosset","doi":"","DOIUrl":null,"url":null,"abstract":"The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 8","pages":"539-42"},"PeriodicalIF":0.0000,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.\",\"authors\":\"Donald Grosset, Andrew Grosset\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 8\",\"pages\":\"539-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在布宜诺斯艾利斯举行的第14届帕金森氏病和运动障碍国际大会的主题涵盖了帕金森氏病和其他运动障碍领域的新治疗发展。本次会议报告重点介绍了运动障碍药物治疗的精选报告，包括沙芬酰胺(Merck Serono SA)， PYM-50028 (Phytopharm plc)， droxidopa, pardopronox (Abbott Laboratories);肌张力障碍的治疗考虑;利用现有药物开发新的适应症;并利用遗传学来评估药物治疗的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.

The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊